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1. Introduction 
Dementia is a brain disorder characterized by a decline in several higher mental functions 
(e.g. memory, intellect, personality) that causes significant impairments in daily functioning 
(Kuljis, 2007). The prevalence of dementia rises with age, doubling every 5 years between 
the ages of 60 and 90 (Corrada et al., 2008). Based on the epidemiological data, dementia is 
widely recognized as a major medical, social and economic problem in developed countries 
where the age over 65 accounts for an increasingly high percentage of the dementic 
population (Breitner et al., 2009). Unfortunately, dementia is now becoming a major 
problem in developing countries where it did not exist 50 years ago (Zilkens et al., 2009). 
More than 50 million people worldwide have dementia and the most common and 
irreversible cause of this dementia is Alzheimer's disease (AD) (Adlard et al., 2009). AD is a 
neurodegenerative disorder divided into two forms namely familial (FAD) and sporadic 
(SAD) cases characterized by cognitive deficits and extensive neuronal loss in the central 
nervous system (CNS) (Michon et al., 2009; Reed et al., 2009) and at the molecular level by 
the presence of specific cytoskeletal abnormalities, including intracellular neurofibrillary 
tangles (NFT) formed by hyperphosphorylated tau protein and the presence of high levels 
of the 40- and 42-amino acid long amyloid beta (A) (Woodhouse et al., 2009). The early 
onset form (i.e. FAD) has a strong genetic correlation that exists between characteristic 
features of AD pathogenesis and mutations in amyloid precursor protein (APP), (Bernardi et 
al., 2009), presenilin (PS-1) and PS-2 (Huang et al., 2009). Of particular interest, the other 
form of AD, SAD is a multifactorial disease to which both genetic and epigenetic factors 
contribute (Zawia et al., 2009). The well confirmed genetic factors for SAD are 
apolipoprotein E (APOE) epsilon 4 allele (Wharton et al., 2009) and PS-2 promoter 
polymorphism (Liu et al., 2008). Accumulating data indicates that disturbances of several 
aspects of cellular metabolism appear pathologically important in SAD. Among these, 
increased brain insulin resistance (Salkovic-Petrisic, 2008), decreased glucose utilization and 
energy metabolism are observed in the early stages of the disease (De la Torre, 2008), 
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consequently energy deficit, oxidative stress (Droge and Kinscherf, 2008) and inflammation 
(De la Monte, 2009) in neuronal tissue which further cause neurodegeneration in SAD.  
By understanding some of the pathological aspects of SAD in humans currently, 
intracerebrovetricular (ICV) administration of streptozotocin (STZ) in rats is commonly 
employed to study experimental dementia. Most importantly, subdiabetogenic doses of ICV 
-STZ induce alterations of brain insulin receptor (IR) and its signaling and consequently 
insulin resistant brain state and behavioral, neurochemical, biochemical, morphological, and 
histological changes similar to aging brain (Salkovic-Petrisic, 2008; Ishrat et al., 2009 a, b). 
Further, it has been well demonstrated that ICV -STZ rat model is targeting the functioning 
of brain IR signaling cascade. In brain, decreased levels of glucose/energy metabolism 
particularly in cerebral cortex and hippocampus regions have been reported starting from 3 
weeks following ICV -STZ administration (Pathan et al., 2006) and consequently 
mitochondrial dysfunction (Agrawal et al., 2009). Additionally, a progressive trend towards 
oxidative stress has also been found starting as early as 1 week following the ICV -STZ 
administration (Pathan et al., 2006). In addition to reduced energy metabolism and 
mitochondrial dysfunction, increased free radical generation and subsequent oxidative and 
nitrosative stress which are well reported to impair learning and memory leading to 
cognitive dysfunction (Ishrat et al., 2009 a, b; Tiwari et al., 2009). Furthermore, decreased 
cholinergic transmission (decreased choline acetyltransferase and increased 
acetylcholinesterase activity) has started to be persistently found later on in the 
hippocampus of ICV -STZ treated rats (Blockland and Jolles 1993, Terwel et al., 1995). ICV -
STZ administration has also been associated with certain brain morphological changes 
followed by extensive cell loss and neurodegeneration by induction of specific damage to 
myelinated tract and astrogliosis found 1 week following the treatment regardless the age of 
animals (Sonkusare et al., 2005). Further, ICV -STZ induced reduction in energy availability 
may also results in increase in cytoplasmic calcium (Ca2+) ions (Muller et al., 1998) 
confirmed by pharmacological use of calcium channel blocker (lercanidipine) that markedly 
attenuated behavioral and biochemical alterations in ICV -STZ rats (Sonkusare et al., 2005). 
It is well known that ATP dependent brain functions are markedly affected in energy failure 
and reduced glucose metabolism states. Relevant to this, all these neurochemical and 
structural changes have been observed as early as 2 weeks after ICV -STZ administration 
and reported to still persist 12 weeks accompanied by long term progressive deficits in 
learning and memory (Lannert and Hoyer, 1998, Grunblatt et al., 2007) and play a major role 
in the pathogenesis of SAD. 
2. Dementia – a background 
Dementia is a syndrome that in most cases is caused by an underlying disease of brain 
disorder characterized by a decline in several mental functions e.g. memory, intellect, 
personality that significantly impair daily functioning (Ferri et al., 2005). Dementia is a 
clinical syndrome with multiple etiologies that particularly affects older people (Corrada et 
al., 2008). Up till now, there is a lack of full understanding of the underlying causes and 
molecular mechanisms leading to this progressive form of dementia. Given the seriousness 
of the impact of dementia, the ageing of the world’s population, and that the prevalence of 
dementia increases with age, a lot of attention is understandably now focused on the 
treatments, care services and support arrangements needed by people with dementia and 
their families, both today and over the coming decades.  
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2.1 Dementia prevalence 
Number of older people (taking the conventional definition as aged 65 or over), particularly 
the number of very old people (aged 80 and above) will increase substantially over the next 
fifty years in all countries, although rates of ageing varies greatly between countries. 
Currently 8% of western population is affected from dementia (Zilkens et al., 2009). By 2025 
this figure is expected to double with 71 per cent of these likely to live in developing 
countries, making the need for prevention of an incurable disease crucial. In U.K 20% of the 
population is 65 and older, particularly in England, 16% of the population was aged 65 or 
over and 4% aged 80 or over in 2005. By 2050 it is expected that the number of people aged 
65 or over will grow from 8 million to almost 15 million (by which time this number will 
represent 25% of the projected total population), while the number aged 80 or over will 
grow from 2 million to just over 6 million (equivalent to 10% of the total population) and 10-
15% have mild, early and borderline demented states (Knapp et al., 2007). 
2.2 Dementia symptoms and etiology 
Dementia is caused by a disease that damages tissues in the brain causing disturbed brain 
functioning. Dementia is characterized by reversible and irreversible causes. There are 
several things which could results reversible dementia and these dementia are treatable. 
These include dementia due to long-term substance abuse, tumors that can be removed, 
subdural hematoma, accumulation of blood beneath the outer covering of the brain that 
result of head injury, normal pressure hydrocephalus, hypothyroidism, toxic reactions like 
excessive alcohol or drug use (Tanev et al., 2008), and nutritional deficiencies like vitamin 
B12 and folate deficiencies (Maccioni et al., 2009) Some of the irreversible and non-treatable 
cause of dementia includes diseases that cause degeneration or loss of nerve cells in the 
brain such as AD, PD (Tong et al., 2009), and HD (Wang et al., 2009), multi-infracts dementia 
(dementia due to multiple small strokes, also known as vascular dementia) (de la Torre et 
al., 2008), infections that affect the brain and spinal cord, such as acquired-immune 
deficiency syndrome (AIDS) dementia complex (Varatharajan and Thomas, 2009) and 
Creutzfeldt-Jakob disease. Some people have a combined type of dementia involving both 
AD and vascular dementia (Tsuno, 2009). 
The most common symptoms that are mostly associated with dementia are delirium from a 
sudden medical problem, psychosis, aggression, anger, insomnia or “sundowning” 
(confusion in late afternoon or early evening), anxiety, depression, and pain from arthritis 
(Kuller et al., 2008). 
3. Alzheimer’s Disease – a type of dementia 
Alzheimer’s disease is the most common dementia in the elderly population (> 65 years) 
associated with progressive neurodegeneration of the central nervous system (CNS) 
(Blennow et al., 2006). Clinically, AD typically begins with a subtle decline in memory and 
progresses to global deterioration in cognitive and adaptive functioning (Watson and Craft, 
2004). The majority of AD cases occur sporadically, what suggested that they could arise 
through interactions among various genetic and environmental factors. Current 
epidemiological investigations show that midlife hypertension, cardiovascular diseases, 
hypercholesterolemia, diabetes, obesity, inflammation, and viral infections can significantly 
contribute to the development and progression of AD, whereas active engagement in social, 
mental and physical activities may delay the onset of the disease (Zawia et al., 2009). 
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3.1 AD prevalence 
AD is the sixth leading cause of all deaths in the United States, and the fifth leading cause of 
death in Americans aged 65 and older. Whereas other major causes of death have been on the 
decrease, deaths attributable to AD have been rising dramatically. Between 2000 and 2006, 
deaths attributable to AD increased 47%. An estimated 5.3 million Americans have AD; the 
approximately 200,000 persons under age 65 years with AD comprise the younger-onset AD 
population. The prevalence of AD increases with age from 4% in the 65 to 75 years age group 
to 19% in the 85 to 89 years age group, and the incidence of AD increases from 7/1000 in the 65 
to 69 years age group to 118/1000 in the 85 to 89 years age group (Fernandz et al., 2008). Every 
70 seconds, someone in America develops AD; by 2050, this time is expected to decrease to 
every 33 seconds. Over the coming decades, the "baby-boom" population is projected to add 10 
million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a 
million people per year with a total estimated prevalence of 11 to 16 million people 
(Alzheimer’s disease Facts and Figures, 2009). A minority of around 400 families worldwide 
can be grouped as familial in origin, whereas the majority of all Alzheimer cases (approx. 25 
million worldwide) are sporadic in origin whose clinical manifestation appear in old age and 
ultimately affects almost half of the population over age 85 (Hoyer and lannert, 2007). 
3.2 Symptoms and stages of AD 
AD can affect different people in different ways, but the most common symptom pattern 
begins with gradually worsening difficulty in remembering new information. This is 
because disruption of brain cells usually begins in regions involved in forming new 
memories (Ramani et al., 2006). In early mild and moderate stages of the disease, people 
may experience irritability, anxiety or depression. In later severe stages, other symptoms 
may occur including sleep disturbances, physical or verbal outbursts, emotional distress, 
restlessness, pacing, shredding paper or tissues and yelling, delusions (firmly held belief in 
things that are not real), and hallucinations (seeing, hearing or feeling things that are not 
there). As damage spreads, individuals also experience confusion, disorganized thinking, 
impaired judgment, trouble expressing themselves and disorientation to time, space and 
 
 
Fig. 1.  
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location, which may lead to unsafe wandering and socially inappropriate behavior. In 
advanced AD peoples need help with bathing, dressing, using the bathroom, eating and 
other daily activities. Those in the final stages of the disease lose their ability to 
communicate, fail to recognize loved ones and become bed-bound and reliant on care 
Various symptoms and stages of AD is summarized in Fig.1.  
3.3 Types of AD 
AD is classified into two types based on etiology, onset of symptoms, pathophysiological, 
biochemical and genetic alterations into familial (FAD) and sporadic (SAD) cases (Reed et 
al., 2009). 
3.3.1 Early onset familial type AD 
The first one is the very rare autosomal dominant early-onset familial type (FAD) is caused 
by missense mutations in the amyloid precursor protein (APP) gene on chromosome 21, in 
the presenilin (PS)-1 gene on chromosome 14 and in the PS -2 gene on the chromosome 1 
(Bernardi et al., 2009). The genetic abnormalities on chromosomes 1, or 14, or 21 are all 
characterized by the permanent generation of amyloid beta (A) 1–40 and in particular A1–
42, beginning early in life (Patterson et al., 2008). Both these derivatives of APP reduce the 
binding of insulin to its receptor and receptor autophosphorylation (Xie et al., 2002). The 
disruption of autophosphorylation by ATP may result in a decrease/lack of receptor 
tyrosine kinase activity and, thus, in a failure of postreceptor effects exerted via insulin 
receptor substrate (IRS)-1 (de la Monte, 2008). This dysfunction of the insulin signal 
transduction cascade may cause a drastic fall in the cerebral metabolism of glucose in FAD 
(Gandy, 2005). Regardless the primary cause and clinical form of AD, the amyloid cascade 
hypothesis proposes that both conditions lead to Aß 1-42 accumulation, oligomerization and 
plaque formation, which further initiates a whole range of pathological cascade effects; 
microgliosis and astrocytosis (Norris et al., 2005), inflammatory response (Kamer et al., 
2008), oxidative and nitrosative stress (Mangialasche et al., 2009), Ca+ dysregulation (Small 
et al., 2009), mitochondrial dysfunction (de la Monte, 2008), neuronal/neuritic dysfunction, 
cell death (Wang et al., 2008), neurotransmitter deficits (Ding  et al., 1992), and finally, 
memory loss (Erol et al., 2008;). In parallel, oxidative stress and neurotransmitter deficits 
induce kinase/phosphatase activity imbalance (Gella and Durany, 2009) which at the level 
of tau protein (microtubule-associated protein that stimulates the generation and 
stabilization of microtubules within cells, and control axonal transport of vesicles results in 
accumulation of hyperphosphorylated tau protein and formation of NFT which contribute 
to memory loss (Mckee et al., 2008).  
3.3.2 Late-onset sporadic type AD 
In contrast to early onset FAD, aging is the main risk factor for late-onset SAD. Aging of the 
brain is associated with a multitude of inherent changes in cerebral glucose/energy 
metabolism, its control, and related pathways at cellular, molecular and genetic levels 
(Placnica et al., 2009). Numerous changes are accentuated by stress particularly functional 
imbalances of regulative systems, such as (1) energy production (reduced) and energy 
turnover (increased), (2) insulin action (reduced) and cortisol action (increased) due to a 
shift in the  hypothalamic pituitary–adrenal axis to an increased basal tone (Cizza et al., 
1994), (3) acetylcholine action (reduced) and noradrenaline action (increased), indicating 
sympathetic tone, obviously also reducing insulin secretion after glucose stimulation (Erol et 
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al., 2008) and (4) shift in the gene expression profile from anabolic (reduced) to catabolic 
(increased) in distinct brain areas such as cortex , hippocampus and hypothalamus (Xu et 
al., 2006) (Fig.2). 
 
 
Fig. 2.Various neurochemical alterations in AD brain 
4. Sporadic type AD associated alterations 
4.1 Changes of the brain insulin signaling cascade  
Research of the brain insulin system has been more pronounced in the last decade, 
particularly regarding its function in the brain. There is a growing interest in finding the role 
of neuronal insulin signaling cascade in the brain, and off course in the brain of SAD. Recent 
data indicate that brain insulin deficiency and insulin resistance brain state are related to the 
late onset SAD (Shaw and Hoglinger, 2007). In line with this decreased brain insulin protein 
and its mRNA levels were found post mortem in the brain (frontal cortex, hippocampus 
(Lester Coll et al., 2006), while IR density was found to be increased and tyrosine kinase 
activity decreased (Frlolich et al., 1998). Interestingly, strikingly reduced expression of genes 
encoding insulin like growth factor-1 (IGF-1) and IGF-1 receptor has also been found in the 
frontal cortex, hippocampus and hypothalamus of patients with AD post mortem (Steen et 
al., 2005). Regarding the downstream IR signaling pathways, reduced levels of PI3-K have 
been found (Dong et al., 2009). Regional specificity of changes and difference in AD severity 
stage probably account for some inconsistency in results reported in relation to Akt/PKB 
and GSK-3/ alterations, whose phosphorylated form were mainly found to be decreased 
(Giese, 2009). In line with this, increased activity of GSK-3 found in hippocampus and 
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hypothalamus could be related to decreased activity of Akt/PKB found in the same regions 
(Steen et al., 2005). Recent data have pointed to another important enzyme, involved in tau 
dephosphorylation, the protein phosphatase 2A (PP2A), which can directly 
dephosphorylate tau (Liang et al., 2009; Martin et al., 2009). It has been revealed a significant 
reduction in the total amount of PP2A in frontal and temporal cortices of SAD patients. 
Thus, it seems likely that hyperphosphorylated tau formation is the consequence of 
increased GSK-3 (Peineau et al., 2008) (Fig.3).  
 
 
Fig. 3. Impairment of Insulin signaling in Alzheimer’s disease 
4.2 Reduced glucose and energy 
Early and severe abnormalities were found in cerebral glucose metabolism which worsened 
in parallel with the dementia symptoms (Maurer and Hoyer, 2006). It includes the 
diminished activity of the pyruvate dehydrogenase complex yielding reduced levels of 
acetyl-CoA (Lannert et al., 1998). As a consequence, the reduced glycolytic glucose 
breakdown, the formation of fructose-6-phosphate may be diminished so that the 
availability of uridine-diphospho-N-acetylglucosamine (UDP-GlcAc) necessary for protein-
O-GlcNAcylation is decreased (Gong et al., 2006). Another pathophysiological consequence 
of the markedly perturbed glucose metabolism is the fall of ATP production from glucose by 
around 50% in the beginning of SAD, declining thereafter throughout the course of the 
disease (de la Torre, 2008). 
4.3 Reduced ATP availability 
A decisive pathophysiological consequence of the markedly perturbed glucose metabolism 
is a decrease in ATP production from glucose by around 50% in the beginning of SAD. The 
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oxidative utilization of substrates other than glucose restores ATP formation to 80% of 
normal, but thereafter ATP levels decrease throughout the course of the disease (Hoyer, 
2004). This energy deficit may compromise ATP-dependent processes in a hierarchical 
manner including cellular and molecular mechanisms in particular in the endoplasmic 
reticulum and Golgi apparatus (Greenfield et al., 1999). A depletion of cellular ATP prevents 
the dissociation of chaperone/protein complexes and thus blocks secretion of these proteins 
(Dorner et al., 1990). Additionally, ATP depletion results in the degradation of membrane 
phospholipids (Sun et al., 1993). 
4.4 Acetylcholine neurotransmission changes  
Oxidative energy metabolism is important for the undisturbed function and structure of the 
brain. Both the neurotransmitter acetylcholine (ACh) and the membrane sterol constituent 
cholesterol are derived from the glucose metabolite, acetyl-CoA (Hellweg et al., 1992). As a 
result of the deficits in glucose and energy metabolism and due to the reduced activity of 
choline acetyltransferase (ChAT), the synthesis of ACh in the presynaptic neuron is 
markedly diminished (Hoyer, 1992).  
5. Neuropathological hallmarks of AD 
Two main neuropathological hallmarks are found in the brain of patients with familial and 
sporadic AD is (1) NFT and (2) amyloid plaques (Woodhouse et al., 2009) (Fig.4).  
 
 
Fig. 4. Neuropathological hallmarks of Alzheimer’s Disease 
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5.1 Tau protein 
NFT consist of intracellular protein deposits made of hyperphosphorylated tau protein 
(Blennow et al., 2006). Tau protein is a microtubule-associated protein which is involved in 
stabilization and promotion of microtubules but when hyperphosphorylated it gains a toxic 
function which is lethal for the neurons (Iqbal et al., 2005). There is a growing body of 
evidence that changes in insulin and insulin receptor (IR) signaling cascade in the brain of 
people with AD and have an influence on the metabolism of APP and A accumulation and 
in maintaining of balance between phosphorylated and non-phosphorylated tau protein 
(Wegiel et al., 2008). 
5.2 Amyloid beta 
Extracellular amyloid plaques predominantly consist of aggregates of neurotoxic A 1-42 
generated in vivo by specific, proteolytic cleavage of APP (Bernardi et al., 2009). Classical 
and also leading amyloid cascade hypothesis assumes that pathological assemblies of A are 
the primary cause of both AD forms and all other neuropathological changes (cell loss, 
inflammatory response, oxidative stress, neurotransmitter deficits and at the end loss of 
Cognitive function are downstream consequences of A accumulation (Bamburg and 
Bloom, 2009).  
6. Intracerebroventricular streptozotocin induced neurotoxicity: An animal 
model of SAD  
Considering the presence of insulin (from both periphery and brain) and IRs in the brain, an 
experimental rat model was developed by using streptozotocin (STZ) administered 
intracerebroventricularly (ICV) in doses of up to 100 times lower (per kg body weight) than 
those used peripherally to induce an insulin resistant brain state (Duelli et al., 1994; Lannert 
and Hoyer, 1998). ICV -STZ rodent model is produced by a single or multiple (up to 3 times 
within one month) injections of a cytotoxic drug STZ, bilaterally into the lateral cerebral 
 
 
Brain pathology STZ-ICV rat model Human SAD 
Behavioral 
Cognitive deficits 
Decrease memory and learning Dementia 
Morphological 
gliosis and synaptic loss 
+ 
+ 
+ 
+ 
Metabolic 
Glucose / energy 
Decrease metabolism Decrease metabolism 
Neurochemical 
Oxidative stess 
Ach transmission 
Insulin receptor signailing 
+ 
Decreased 
brain insulin resistance state 
+ 
Decreased 
brain insulin resistance state 
Neuropathological 
Thau protein 
Amyloid beta 
+ 
+ 
+ 
+ 
(Salkovic-Perisic, 2008) 
Table. 1. Similarities between ICV -STZ Model and Human SAD. 
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ventricle of an adult rat, first reported in 1990 (Mayer et al., 1990). Although learning and 
memory are impaired within 4 weeks in all experimental models of AD (Weinstock and 
Shoham, 2004), however, no single model was determined to be truly representative of SAD 
characterized by abnormalities in neuronal IRs signaling. ICV -STZ reproduces a number of 
important aspects of SAD-type neurodegeneration within 1 month of ICV -STZ injection(s) 
and therefore provides supportive evidence that SAD may be caused in part by neuronal 
insulin resistance, i.e. brain diabetes (Salkovic et al., 2006). 
STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose) is a drug selectively toxic for 
insulin producing/secreting cells both in the periphery as well as in the brain (Hoyer and 
Nitsch, 1989) and consequently ICV -STZ impairs the insulin-IR system (Blokland and Jolles, 
1993). Reflection on some of the earlier findings in AD, including the impaired glucose 
utilization, mitochondrial dysfunction, reduced ATP production, and energy dysregulation 
prompted consideration of the hypothesis that these abnormalities were mediated by 
desensitization of the neuronal IRs (Duelli et al., 1994; de la Monte et al., 2006). The stated 
metabolic abnormalities, as well as several of the classical histopathological lesions of AD, 
could be attributed in part to reduced insulin levels and reduced IR function in AD. Seigfried 
Hoyer was among the first to suggest that reduced levels of brain insulin may precipitate a 
cascade resulting in disturbances in cellular glucose, Ach, cholesterol and ATP levels, impaired 
membrane function, accumulation of amyloidogenic derivatives, and hyperphosphorylation of 
tau, i.e. that SAD may represent a brain form of type 2 diabetes mellitus (Hoyer and Riederer, 
2007; Li and Holscher, 2007). A comparison and correlation of various pathological changes 
observed in human SAD and ICV -STZ rat model are summarized in Table 1.   
6.1 Peripheral mechanism of streptozotocin 
In the periphery, STZ causes selective pancreatic  cell toxicity results from the drug’s 
chemical structure which allows it to enter the cell via the GLUT2 glucose transporter. The 
 
 
 
Fig. 5. Peripheral mechanism of streptozotocin. 
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predominant site of GLUT2 localization is the pancreatic beta cell membrane (Szkudelski, 
2001). Following peripheral administration, STZ causes alkylation of -cell DNA which 
triggers activation of poly ADP-ribosylation, leading to depletion of cellular NADH and 
ATP (Szkudelski, 2001). When applied intraperitoneally in high doses (45-75 mg/kg) STZ is 
toxic for insulin producing/secreting cells, which induces experimental DM type 1. Low 
doses (20-60 mg/kg) of STZ given intraperitoneally in neonatal rats damages IR and alters 
IR signaling and causes diabetes mellitus type 2 (Blondel and Portha, 1989) (Fig.5). 
6.2 Central mechanism of action of streptozotocin 
Central STZ administration caused neither systemic metabolic changes nor diabetes 
mellitus. STZ has been administrated mostly in doses ranging from 1–3 mg/kg body 
weight, injected 1–3 times, either uni-or bi-laterally into the lateral cerebral ventricles. 
Identical biochemical changes have been found in the left and right striatum after 
administration of STZ into the right lateral cerebral ventricle only (Prickaerts et al., 2000, 
Deshmukh et al., 2009). The mechanism of central STZ action and its target cells/molecules 
have not yet been clarified but a similar mechanism of action to that in the periphery has 
been recently suggested. GLUT2 may also be responsible for the STZ induced effects in the 
brain as GLUT2 also is reported to have regional specific distribution in the mammalian 
brain (Arluison et al., 2004a, b). The chemical structure of STZ also suggests this compound 
may produce intracellular free radicals, nitric oxide (NO) and hydrogen peroxide 
(Szkudelski, 2001) and induces behavioral, neurochemical and structural changes that are 
similar to those found in SAD (Fig. 6).  
 
 
Fig. 6. Central mechanism of action of intracerebroventricularly administered streptozotocin 
in rats. 
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6.2.1 ICV -STZ induced Insulin signaling alteration  
Substantial evidence has been gathered in support of the presence of both insulin and IRs in 
the brain, and of insulin action. The main source of brain insulin is the pancreas crossing the 
blood–brain barrier by a saturable transport mechanism (Hoyer, 2004). A smaller proportion 
of insulin is produced in the brain itself (IR signaling cascade in the brain) is similar to the 
one at the periphery. There are two main parallel IR intracellular pathways, the (PI-3K) 
pathway and the mitogen activated protein kinase (MAPK) pathway (Johanston et al., 2003, 
Mehan et al., 2010a,b). When insulin binds to the subunit of IR it induces 
autophosphorylation of the intracellular -subunit resulting in increased catalytic activity of 
the tyrosine kinase (Johanston et al., 2003). Now activated IR becomes a docking site for the 
IRS, which then becomes phosphorylated on tyrosine residues. IRS is now ready to bind 
various signaling molecules with SH2 domains; one of these molecules is (PI-3K). After 
being activated, PI-3K induces phosphorylation and subsequent activation of protein kinase 
B (Akt/PKB), consequently activated Akt/PKB triggers glucose transporter 4 (GLUT4) and 
also phosphorylates the next downstream enzyme glycogen synthase kinase (GSK-3) which 
then becomes inactive (Johanston etal., 2003) (Fig.7).  
 
 
Fig. 7. Brain insulin receptor signaling cascade in the insulin resistant brain state induced by 
the intracerebroventricular streptozotocin treatment. 
Akt/PKB: protein kinase B; APP: amyloid precursor protein; A: amyloid beta; GSK-3: 
glycogen synthase kinase-3; GSK-3-P: phosphorylated glycogen synthase kinase-3; IR: Insulin 
receptor; IGF-1R: insulin-like growth factor-1 receptor; IRS: insulin receptor substrate; tau: tau 
protein; tau-P: phosphorylated tau protein; MAP-K: mitogen activated protein kinase; PI3-K: 
phosphatidylinositol- 3 TK: tyrosine kinase; kinase; SAD: human sporadic Alzheimer’s 
disease; ICV -STZ intraverebroventricularl streptozotocin (Salkovic-Petrisic and Hoyer, 2007). 
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It has been reported that changes in the brain insulin and tau-A systems are observed 
following the bilateral application of a single or multiple 1 mg/kg STZ dose into the lateral 
cerebral ventricles of adult 3 month old rats (Salkovic-Petrisic et al., 2006). Since treatment 
with very low to moderate doses of STZ in short term experiments causes insulin resistance 
(Blondel and Portha, 1989) via a decrease in autophosphorylation and decrease in total 
number of IRs, but with little change in phosphorylated IR- subunit (Droge and Kinscherf, 
2008). Indeed, the activity of the protein tyrosine phosphatase decreased after long-term 
STZ-damage (Mayerovitch et al., 1989) and induced a drastic reduction of IR 
dephosphorylation (Pathan et al., 2006). 
 
 
Fig. 8. Brain insulin receptor signaling casscade in physiological conditions. 
Regarding the enzymes downstream of the IR-PI3-K pathway, experiments have shown 
alterations of hippocampal GSK-3ß however, observed changes were of a greater extent in the 
phosphorylated than in the non-phosphorylated form of GSK-3 (Lester Coll et al., 2006). The 
IR protein was decreased in the frontoparietal cortex and hypothalamus, but the levels of 
phosphorylated IR (p-IR) were increased and tyrosine kinase activity was unchanged in 
these regions, whereas in the hippocampus IR protein levels were decreased, but p-IR 
levels, as well as tyrosine kinase activity were increased (Grunblatt et al., 2007). Downstream 
from the PI3-K signaling pathway, hippocampal Akt/PKB remained unchanged at 4 weeks 
and decreased by 12 weeks post-treatment, whereas in the frontoparietal cortex Akt/PKB 
expression was decreased 4 weeks and increased by 12 weeks post ICV -STZ treatment. 
Regarding the phosphorylated GSK-3 (pGSK-3) form, levels in hippocampus were increased 
after 1 month, but decreased 3 months after the STZ treatment, while in the frontal cortex, 
pGSK-3 was found to be decreased in both observational periods, 1 and 3 months following 
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the ICV -STZ treatment (Salkovic-Petrisic and Hoyer, 2007). In this regard, many molecular 
abnormalities that characteristically occur in AD, including increased GSK-3 activation, 
increased tau phosphorylation, and decreased neuronal survival, could be mediated by 
downstream effects of impaired insulin and IGF signaling in the CNS (Fig. 8).  
[A: amyloid beta; Akt/PKB: protein kinase B; APP: amyloid precursor protein; GSK-3: 
glycogen synthase kinase-3; GSK-3-P: phosphorylated glycogen synthase kinase-3; IGF-1R: 
insulin-like growth factor-1 receptor; IR: Insulin receptor; IRS: insulin receptor substrate; 
MAPK: mitogen activated protein kinase; PI3-K: phosphatidylinositol-3 kinase; tau: tau 
protein; tau-P: phosphorylated tau protein; TK: tyrosine kinase]. 
6.2.2 ICV-STZ induced glucose/energy metabolism changes  
ICV administration of STZ clearly shows heterogeneous changes in local cerebral glucose 
utilization after single bilateral injection in to brain ventricles in all region of cerebral cortex, 
in particular parietal cerebral cortex (-19%) and frontal cerebral cortex (-13%) where 
concentration of ADP, as well as glycogen and lactate level, were increased in the cerebral 
cortex and in the hippocampus regions (Nitsch and Hoyer, 1991). In addition, significantly 
diminished the activities of glycolytic enzymatic hexokinase and phosphofructokinase by 15 
and 28% respectively, in parietotemporal cerebral cortex and hippocampus activity and 10-
30% in brain cortex and hippocampus 3 and 6 weeks post ICV -STZ administration 
(Plaschke and Hoyer, 1993). This pathologic condition, obviously sparing the metabolism in 
the tricarboxylic acid (TCA) cycle, seems to be characteristic of SAD (Plaschke and Hoyer, 
1993) resulting in diminished concentration of the energy rich compounds ATP and creatine 
phosphate (Lannert and Hoyer., 1998). Interestingly, the extent of the shortage in energy 
production was the same in the STZ-damaged brain as in incipient SAD (Ishrat et al., 2006).  
6.2.3 ICV-STZ induced oxidative stress 
ICV -STZ treatment causes marked reduction in brain glucose/energy metabolism and shows 
a progressive trend towards oxidative stress (Lannert and Hoyer 1998). Growing body of 
evidences indicate that STZ treatment generates reactive oxygen species (ROS) that results in  
increased oxidative stress and additionally releases NO in brains of ICV -STZ treated rats 
(Shoham et al., 2007). Estimation of oxidative stress induced by ICV -STZ treatment commonly 
utilize the measurement of levels of MDA, a product of lipid peroxidation used as an indicator 
of free radical generation, and GSH levels, an endogenous antioxidant that scavengers free 
radicals and protect against oxidative and nitrative  stresses. Relevant to this oxidative-
nitrative stress has been found 1 and 8 weeks following a single 3 mg/kg ICV -STZ dose 
without involvement of NO (Shoham et al., 2003). Besides oxidative stress was also found in 
the brain of one year old rats, 3 weeks following a lower single ICV -STZ dose 1.5 mg/kg. 
Significant alteration in the markers of oxidative damage thiobarbituric acid (TBARS), GSH, 
protein carbonylation (PC), glutathione peroxidase (GPx), glutathione reductase (GR) and 
decline in the level of ATP were observed in hypothalamus and cerebral cortex, monitored 2-3 
weeks after  ICV -STZ application (Ishrat et al., 2009 a,b). A recent study demonstrated the 
beneficial effects of pioglitazone in the ICV - STZ induced cognitive deficits, which can be 
exploited for the treatment of dementia associated with diabetes and age-related 
neurodegenerative disorder, where oxidative stress and impaired glucose and energy 
metabolism are involved (Pathan et al., 2006). This is also supported by the use of naringenin 
(Balchenejadmojarad and Roghani, 2006), gugulipid (Saxena et al., 2007), melatonin (Sharma 
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and Gupta 2001a ), ascorbic acid (Weerateerangukul et al., 2008), mefenamic acid (Mojarad et 
al., 2007), transresveratol (Sharma and Gupta, 2002), lipoic acid (Sharma and Gupta, 2003), 
Centella asiatica (Kumar and Gupta., 2003), Ginkgo biloba (Hoyer et al., 1999), CoQ10 (Ishrat et 
al., 2006), ladostigil (Shoham et al., 2007), melatonin and donepezil (Agarwal et al., 2009), 
curcumin (Ishrat et al., 2009a) and selenium ((Ishrat et al., 2009 b) which prevented or reduced 
ICV-STZ induced behavioral, neurochemical and histological alterations via reducing free 
radical generation, scavenging free radicals, restoring endogenous antioxidant defenses. These 
data strongly suggest antioxidant strategies in ameliorating SAD.  
6.2.4 ICV-STZ induced neurotransmission deficits 
The most studied neurochemical alteration in ICV -STZ injected rats is cholinergic deficit in 
the brain, without morphological changes in cholinergic neurons important for learning and 
memory (Spencer and Lal, 1983). ICV -STZ treated rats showed an impaired learning and 
memory performance, possibly as a result of cholinergic dysfunction ( Nitsch and Hoyer, 
1991). Apart from this, Blokland and Jolles (1993, 1994), found spatial learning deficit and 
reduced hippocampal ChAT activity in rats one week after ICV -STZ injection (Prickaerts et 
al., 1999). A decrease in ChAT activity has been consistently found in the hippocampus of 
ICV -STZ treated rats as early as 1 week following STZ treatment and is still present 3 weeks 
post-injection (Hellweg et al., 1992). This is followed by a significant increase in 
acetylcholinesterase (AChE) activity (Agarwal et al., 2009). A decrease in hippocampal 
ChAT activity was completely prevented by 2-weeks of orally administered acetyl-L-
carnitine, which acts by enhancing the utilization of alternative energy sources (Terwel et 
al., 1995). Chronic administration of cholinesterase inhibitors Donepezil, Ladostigil and 
Donepezil along with melatonin reduced AChE activity in a dose-dependent manner in 
ICV-STZ treated rats regardless of whether treatment began 1 week prior to, in parallel or 13 
days after ICV -STZ administration (Sonkusare et al., 2005).  
ICV injections of STZ affect not only the cholinergic system but also the concentration of 
different monoaminergic neurotransmitters (noradrenaline, dopamine, and serotonin) in the 
rat brain differently (Salkovic-Petristic and Lackovic, 2003; Levine et al., 1990). It has been 
reported that the content of whole brain monoamine (dopamine, noradrenaline, serotonine 
(5-hydroxy tryptamine) and 5-HT metabolite 5-hydroxyindoleacetic acid (5HIAA) dose-
dependently increased and decreased, respectively, 1 week following ICV -STZ treatment 
(Salkovic-Petristic and Lackovic, 2003).  
6.2.5 ICV-STZ induced behavioral alterations  
ICV-STZ treated rats consistently demonstrate deficits in learning, memory, and cognitive 
behavior (Table.2). It is well known that ICV -STZ reduced cerebral metabolism of glucose 
and caused impaired cognitive performance in the delayed non-matching task (Prickaerts et 
al., 1995, 1999), passive avoidance (Ishrat et al., 2006, 2009 a, b) and Morris water maze 
escape task 2 weeks after its administration (Blokland and Jolles et al., 1993, 1994). These 
behavioral alterations were observed regardless of age in both 1–2 year (Mayer et al., 1990; 
Lannert and Hoyer, 1998; and 3-month old rats (Grunblatt et al., 2006) and also after either a 
single 1 or 3 mg/kg injection or multiple 1 mg/kg ICV -STZ injections. It is well 
documented that ICV -STZ shows dose-dependency in causing neurotoxicity with lower 
STZ doses induces less severe cognitive deficits (Blokland and Joles, 1994; Prickaerts et al., 
2000; Grunblatt et al., 2006). Most importantly, cognitive deficits are long-term and 
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progressive, observed as early as 2 weeks after ICV -STZ administration and are maintained 
up to 12 weeks post treatment (Shoham et al., 2003). The correlation between spatial 
discrimination performance in the Morris water maze task and the decrease in hippocampal 
ChAT activity which resembles the relationship between cognitive and biochemical 
cholinergic changes observed in SAD has been found in ICV -STZ treated rats (Blokland and 
Jolles, 1994). Chronic treatment with acetyl-L-carnitine attenuated both the STZ induced 
impairment in spatial bias and the decrease in hippocampal ChAT activity (Prickaerts et al., 
1995). Interestingly, it has also been demonstrated that ICV -STZ induces development of 
reactive gliosis and oxidative stress 1 week post-treatment, preceded the induction of 
memory deficits at 3 weeks post-treatment (Sharma and Gupta, 2001b), where no signs of 
neuronal damage or any reduction in specific cholinergic markers were detected in the 
cortex or hippocampus (Shoham et al., 2003). Concordingly, memory deficits were reported 
to be prevented by chronic treatment with several types of drugs with diverse mechanisms 
of action (Weinstock and Shoham, 2004). Adding to this, (a) drugs generating alternative 
energy sources such as acetyl-L-carnitine (Prickaerts et al., 1995), (b) cholinesterase 
inhibitors such as donepezil and ladostigil (possess monoamine oxidase B inhibition and 
neuroprotective activity which also prevent gliosis and oxidative stress (Sonkusare et al., 
2005) (c) estradiol which prevents reduction in cerebral ATP (Lannert et al., 1998) (d) 
antioxidants such as melatonin, resveratrol, and CoQ10 which prevent an increase in free 
radical generation (Sharma and Gupta, 2001c, 2002), dose-dependently improved learning 
and memory thereby restoring cognitive  function without affecting CNS functions. 
6.2.6 ICV-STZ induced structural changes, inflammation and neurodegeneration  
ICV -STZ administration has also been associated with certain brain structural changes in 
the brain as early as 1 week following a single dose (Shoham et al., 2003) and in the brain 
and in both  1 year and 4 month old rats (Terwel et al., 1995). In preliminary studies, glial 
fibrillary acidic protein (GFAP), a marker of gliosis has been found to be increased  in three 
different protein fractions (soluble, triton X-100 soluble in cortical and subcorical structures 
including septum, fornix, and fimbria, striatum, and hippocampus, over a period of 3 weeks 
following ICV -STZ administration (Prickaerts et al., 1999, 2000) suggesting that altered 
hippocampal function could result from direct damage to this region (Prickaerts et al., 2000; 
Shoham et al., 2003). A direct histopathological evidence caused by STZ  by its specific 
neurotoxic damage to axon and myelin in some brain region responsible for learning and 
spatial memory including the fornix, anterior hippocampus and periventricular areas 
independent of its action on glucose metabolism have been reported (Weinstock and 
Shoham , 2004). These pathological features are all present in the brain of SAD patients 
(Frlolich et al., 1998). The most prominent change, seen 3 weeks following ICV -STZ 
injection was a significant enlargement of golgi-apparatus, caused by expansion of trans-
golgi segment of cellular protein secretory pathway in the rat cerebral cortex was found, 
which did not resemble Golgi atrophy found in the brain of SAD patients. Trans part of 
Golgi complex may influence proteolytic processing of ßAPP generated in endoplasmic 
reticulum and in the golgi complex (Greenfield et al., 1999) which accumulated in AD brain.   
6.2.7 ICV-STZ induced A and Tau Hyperphosphorylation  
Regarding brain immunohistochemical analysis of tau protein and A expression, 3 weeks 
following ICV -STZ treatment both the overexpression of tau protein in the leptomeningeal 
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vessels at all of epitopes examined in both cerebral cortex and hippocampus were 
demonstrated 3 weeks after ICV -STZ (Chu and Qian, 2005; Lester-coll et al., 2006;) due to 
insulin depletion by STZ, or caused by activation of multiple kinase/by inhibition of 
phosphatase (PP2A) that dephosphorylate these sites (Martin et al., 2009). 
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